Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR | P30559 | 16/20 | 0.42 |
| ▸ | SMO | Q99835 | 1/20 | 0.41 |
| ▸ | AVPR1A | P37288 | 10/20 | 0.41 |
| ▸ | SLC6A7 | Q99884 | 2/20 | 0.39 |
| ▸ | AVPR2 | P30518 | 4/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | GHSR | Q92847 | 1/20 | 0.39 |
| ▸ | AVPR1B | P47901 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL316997 | 0.90 | SLC6A7 (0.51) | OXTRSMOAVPR1ASLC6A7TACR1 | |
| SCHEMBL8285773 | 0.88 | GPR119 (0.43) | OXTRSMOAVPR1ASLC6A7AVPR2 | |
| SCHEMBL27648789 | 0.85 | SMO (0.43) | SMOSLC6A7 | |
| SCHEMBL316099 | 0.80 | OXTR (0.40) | OXTRSMOAVPR1AAVPR2TACR1 | |
| SCHEMBL315784 | 0.78 | OXTR (0.44) | OXTRAVPR1AAVPR2TACR1OPRK1 | |
| SCHEMBL13292486 | 0.75 | GPR119 (0.43) | OXTRAVPR1AAVPR2TACR1OPRK1 | |
| SCHEMBL315678 | 0.74 | SMO (0.53) | SMOSLC6A7 | |
| SCHEMBL4619815 | 0.72 | OXTR (0.49) | OXTRAVPR1AAVPR2TACR1OPRK1 | |
| SCHEMBL315796 | 0.71 | OXTR (0.45) | OXTRAVPR1AAVPR2KCNH2 | |
| SCHEMBL316872 | 0.71 | OXTR (0.39) | OXTRAVPR1AAVPR2TACR1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093400-B2 | Compounds useful in therapy | PFIZER INC. (US) | 2012-01-10 | — | — | US | disclosed |
| CN-1898244-B | Triazole derivatives as vasopressin antagonists | PFIZER | 2011-06-22 | — | — | CN | disclosed |
| US-20100317652-A1 | Compounds Useful In Therapy | PFIZER INC | 2010-12-16 | — | — | US | disclosed |
| US-7745630-B2 | Triazolyl piperidine arginine vasopressin receptor modulators | BRYANS JUSTIN STEPHEN | 2010-06-29 | — | — | US | disclosed |
| EP-1701959-A1 | TRIAZOLE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | Pfizer Limited (GB) | 2006-09-20 | — | — | EP | disclosed |
| WO-2005063754-A1 | TRIAZOLE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | PFIZER LIMITED (GB) | 2005-07-14 | — | — | WO | disclosed |
| US-20050154024-A1 | Compounds useful in therapy | PFIZER INC | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154024-A1 | Compounds useful in therapy | PTGER4, PTGER3, ALOX5 | OXTR 366/4885SMO 1752/4885AVPR1A 533/4885 |
| US-20100317652-A1 | Compounds Useful In Therapy | AVPR1A, AVPR1B, AVPR2 | OXTR 68/4885SMO 4009/4885AVPR1A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.